Table 3 Comparison of clinical characteristics between patients with reduced PVC group following carvedilol treatment and not
Reduced (n = 18) | Not reduced (n = 7) | P value | |
|---|---|---|---|
Age (years) | 53.6 ± 10.2 | 56.3 ± 17.5 | 0.630 |
Male (%) | 6 (33.3) | 2 (28.6) | 0.822 |
LV EF (%) | 65.3 ± 4.8 | 62.4 ± 5.5 | 0.202 |
LA volume (mm3) | 59.6 ± 22.3 | 62.0 ± 16.7 | 0.802 |
Dose of Dilatrend SR® (mg) | 17.8 ± 9.7 | 19.4 ± 12.1 | 0.725 |
Duration of treatment (days) | 136.3 ± 55.7 | 214.9 ± 141.2 | 0.196 |
Pre-treatment PVC burden (%) | 12.2 ± 9.7 | 7.1 ± 6.1 | 0.213 |
Post-treatment PVC burden (%) | 4.4 ± 6.7 | 9.8 ± 8.4 | 0.101 |